On September 9, 2024, ReciBioPharm, a US-based contract development and manufacturing organization (CDMO) service provider, and Hongene Biotech, a leading supplier in the nucleic acid raw materials field, announced a strategic collaboration. Through this partnership, Hongene Biotech's independently developed high-purity sgRNA synthesis technology will empower ReciBioPharm, delivering higher-quality products and more efficient solutions for gene editing drug development.
Strategic Alliance to Advance Gene Editing Drug Production
Leveraging its extensive experience in nucleic acid manufacturing, Hongene Biotech has pioneered an innovative patented sgRNA synthesis technology. This technology significantly reduces impurities generated in traditional processes, substantially enhancing product purity and quality, marking a major breakthrough in nucleic acid manufacturing processes.
ReciBioPharm operates advanced mRNA production facilities near Boston, Massachusetts, offering clients comprehensive CDMO services spanning from plasmid, mRNA, LNP to sterile drug products, covering the entire process of development, analysis, and GMP production. The company collaborates closely with MIT and has received funding from the US FDA CBER office. Currently at the forefront of mRNA-LNP continuous manufacturing technology, it provides robust technical support for rapid response to future pandemic threats.
Through this strategic alliance, the two companies have created a unique one-stop solution for innovators in the gene editing field. ReciBioPharm will expand its service portfolio to include sgRNA manufacturing, utilizing Hongene Biotech's innovative synthesis process to integrate plasmid, mRNA, sgRNA, LNP, and fill-finish services within a single production facility. This collaboration will significantly streamline development and production processes, reduce logistical complexities associated with multiple service providers, and ultimately accelerate drug development and commercialization timelines.
About Hongene
Hongene Biotech is an enterprise offering end-to-end nucleic acid manufacturing solutions, committed to providing comprehensive products and services for the life sciences industry. From standard gene monomers to complex oligonucleotides and mRNA, Hongene Biotech consistently delivers every product with exceptional quality and value.
Through close collaboration with partners, Hongene Biotech helps unlock the limitless potential of nucleic acids, driving innovative therapeutic solutions worldwide and delivering life-changing medical breakthroughs for patients.
About Hongene
ReciBioPharm is a top-ten global contract development and manufacturing organization (CDMO) dedicated to delivering exceptional services for companies developing and commercializing Advanced Therapy Medicinal Products (ATMPs). The company offers full-spectrum CDMO capabilities from preclinical through clinical to commercial stages, encompassing live virus and viral vector technologies, live microbial biologics, as well as mRNA and plasmid DNA production.
Led by a management team and technical experts with extensive experience in process development and contract manufacturing, ReciBioPharm leverages deep technical expertise and globally leading resources to provide robust support for the development and manufacturing of clients' breakthrough therapies, committed to addressing the treatment needs of patients worldwide.